L5 Capital Inc. Amends BriaCell Therapeutics Stake

TL;DR

L5 Capital Inc. updated its BriaCell Therapeutics stake filing. Watch for potential moves.

AI Summary

L5 Capital Inc. filed an amendment (No. 3) to its Schedule 13D on December 10, 2024, regarding its holdings in BriaCell Therapeutics Corp. The filing indicates a change in the beneficial ownership of BriaCell Therapeutics Corp. common shares. Marc Lustig is identified as the person authorized to receive notices and communications for L5 Capital Inc.

Why It Matters

This amendment signals a potential shift in control or investment strategy for BriaCell Therapeutics Corp., which could impact its stock price and future operations.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate significant shifts in a company's shareholder base, potentially leading to volatility.

Key Players & Entities

• L5 Capital Inc. (company) — Filing entity
• BriaCell Therapeutics Corp. (company) — Subject company
• Marc Lustig (person) — Authorized contact for L5 Capital Inc.

FAQ

Key Financial Figures

• $28,995 — December 6, 2024, L5 Capital Inc. used $28,995 in working capital funds to purchase 30
• $0.9665 — s of common stock on the open market at $0.9665 per share. On December 6, 2024, L5 Ca
• $40,689.50 — December 6, 2024, L5 Capital Inc. used $40,689.50 in working capital funds to purchase 85
• $0.4787 — 0 public warrants on the open market at $0.4787 per public warrant. The public warrants
• $5.31 — immediately, have an exercise price of $5.31 per share, and expire on February 26, 2
• $106,295 — December 3, 2024, L5 Capital Inc. used $106,295 in working capital funds to purchase 23
• $0.4562 — the open market at an average price of $0.4562 per public warrant. The public warrants
• $2.215 — arrants at a combined purchase price of $2.215 per common share and accompanying warra
• $2,000,000 — ant, for an aggregate purchase price of $2,000,000. The securities were purchased by L5 Ca
• $2.11 — ate of issuance at an exercise price of $2.11 and will expire on the five year annive
• $9,421,129.50 — 5 Capital Inc. expended an aggregate of $9,421,129.50 for the purchase of the common shares.
• $5.74 — mber 1, 2026, have an exercise price of $5.74 and vested immediately upon issuance.
• $6.03 — une 20, 2028, have an exercise price of $6.03 and vested immediately upon issuance.
• $67,250 — 2022 for an aggregate purchase price of $67,250. The exercise price is $5.21 and expire
• $5.21 — price of $67,250. The exercise price is $5.21 and expire on February 26, 2026. Item

Filing Documents

• formsc13da.htm (SC 13D/A) — 85KB
• 0001493152-24-049352.txt ( ) — 87KB

From the Filing

SC 13D/A 1 formsc13da.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* BriaCell Therapeutics Corp. (Name of Issuer) COMMON SHARES, NO PAR VALUE (Title of Class of Securities) 10778Y302 (CUSIP Number) Marc Lustig 1 First Canadian Place Toronto, Ontario M5X 1H3 Canada (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 6, 2024 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 10778Y302 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Marc Lustig 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS OO 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(e) or 2(f) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Canada NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 7 SOLE VOTING POWER 140,000 (1) 8 SHARED VOTING POWER 3,813,870 (2) 9 SOLE DISPOSITIVE POWER 140,000 (1) 10 SHARED DISPOSITIVE POWER 3,813,870 (2) 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,953,870 (1) (2) 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 10.5% (3) 14 TYPE OF REPORTING PERSON IN (1) Consists of 140,000 common shares issuable upon the exercise of options held by Marc Lustig. (2) Consists of 2,572,935 common shares, 902,935 common shares issuable upon exercise of warrants and 338,000 common shares issuable upon exercise of public warrants held by L5 Capital Inc. (3) Based on 36,313,161 shares outstanding as of December 4, 2024 and 140,000 common shares issuable upon exercise of options, 902,935 common shares issuable upon exercise of warrants and 338,000 common shares issuable upon exercise of public warrants. 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) L5 Capital Inc. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS WC 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(e) or 2(f) 6 CITIZENSHIP OR PLACE OF ORGANIZATION British Columbia, Canada NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 7 SOLE VOTING POWER 0 8 SHARED VOTING POWER 3,813,870 (1) 9 0 10 SHARED DISPOSITIVE POWER 3,813,870 (1) 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,813,870 (1) 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 10.2% (2) 14 TYPE OF REPORTING PERSON CO (1) Consists of 2,572,935 common shares, 902,935 common shares issuable upon exercise of warrants and 338,000 common shares issuable upon exercise of public warrants held by L5 Capital Inc. (2) Based on 36,313,161 shares outstanding as of December 4, 2024 and 902,935 common shares issuable upon exercise of warrants and 338,000 common shares issuable upon exercise of public warrants. Item 1. Security and Issuer This Amendment No. 3 to Schedule 13D amends and supplements the Schedule 13D initially filed with the Securities and Exchange Commission on September 7, 2021 , as previously amended by Amendment No. 1 filed on May 24, 2024 and Amendment No. 2 filed on December 5, 2024, with respect to the common shares, no par value, of BriaCell Therapeutics Corp., a British Columbia corporation (the “Issuer”). The address of the principal executive office of the Issuer is Suite 300 – 235 15th

View Full Filing

View this SC 13D/A filing on SEC EDGAR